Abbott Laboratories Future Growth

Future criteria checks 2/6

Abbott Laboratories is forecast to grow earnings and revenue by 11.8% and 6.5% per annum respectively. EPS is expected to grow by 11.9% per annum. Return on equity is forecast to be 21.5% in 3 years.

Key information

11.8%

Earnings growth rate

11.9%

EPS growth rate

Medical Equipment earnings growth	17.5%
Revenue growth rate	6.5%
Future return on equity	21.5%
Analyst coverage	Good
Last updated	11 Aug 2024

Recent future growth updates

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Jan 26

Recent updates

A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Aug 16

Abbott Laboratories: Driving Value By Scaling Innovations

Aug 13

Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors

Aug 05

Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough

Jul 13

These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Jul 01

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Jun 18

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Jan 26

Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King

Dec 28

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Dec 27

Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio

Dec 03

Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?

Nov 29

Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market

Nov 26

Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?

Nov 01

Earnings and Revenue Growth Forecasts

NYSE:ABT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	48,079	7,805	8,985	10,977	20
12/31/2025	44,771	6,827	8,654	10,188	23
12/31/2024	41,743	5,810	10,091	11,462	22
6/30/2024	40,725	5,535	5,654	7,900	N/A
3/31/2024	40,326	5,608	4,923	7,143	N/A
12/31/2023	40,109	5,701	5,059	7,261	N/A
9/30/2023	39,959	5,153	4,492	6,549	N/A
6/30/2023	40,226	5,151	5,488	7,452	N/A
3/31/2023	41,505	5,785	6,823	8,659	N/A
12/31/2022	43,653	6,905	7,804	9,581	N/A
9/30/2022	45,030	7,857	8,541	10,322	N/A
6/30/2022	45,548	8,520	8,468	10,243	N/A
3/31/2022	44,514	7,695	8,152	9,961	N/A
12/31/2021	43,075	7,042	8,648	10,533	N/A
9/30/2021	42,308	7,208	9,314	11,264	N/A
6/30/2021	40,233	6,343	8,644	10,629	N/A
3/31/2021	37,338	5,693	7,609	9,823	N/A
12/31/2020	34,608	4,449	5,724	7,901	N/A
9/30/2020	32,221	3,346	4,587	6,519	N/A
6/30/2020	31,444	3,073	4,564	6,401	N/A
3/31/2020	32,095	3,539	4,476	6,139	N/A
12/31/2019	31,904	3,666	4,498	6,136	N/A
9/30/2019	31,355	3,272	3,814	5,485	N/A
6/30/2019	30,935	2,867	4,096	5,720	N/A
3/31/2019	30,723	2,582	4,450	5,904	N/A
12/31/2018	30,578	2,319	4,906	6,300	N/A
9/30/2018	30,402	802	4,903	6,175	N/A
6/30/2018	29,575	812	4,816	5,997	N/A
3/31/2018	28,445	365	N/A	6,104	N/A
12/31/2017	27,390	344	N/A	5,570	N/A
9/30/2017	25,134	1,971	N/A	5,100	N/A
6/30/2017	23,607	1,055	N/A	4,312	N/A
3/31/2017	22,303	1,384	N/A	3,870	N/A
12/31/2016	20,853	1,056	N/A	3,203	N/A
9/30/2016	20,708	989	N/A	2,861	N/A
6/30/2016	20,556	1,939	N/A	2,839	N/A
3/31/2016	20,393	2,124	N/A	2,871	N/A
12/31/2015	20,405	2,586	N/A	2,966	N/A
9/30/2015	20,573	2,523	N/A	3,376	N/A
6/30/2015	20,502	2,365	N/A	3,382	N/A
3/31/2015	20,389	2,004	N/A	3,341	N/A
12/31/2014	20,247	1,710	N/A	3,675	N/A
9/30/2014	19,905	1,560	N/A	4,062	N/A
6/30/2014	19,651	1,762	N/A	3,383	N/A
3/31/2014	19,034	1,654	N/A	3,200	N/A
12/31/2013	19,657	1,970	N/A	3,324	N/A
9/30/2013	20,275	961	N/A	3,202	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABT's forecast earnings growth (11.8% per year) is above the savings rate (2.5%).

Earnings vs Market: ABT's earnings (11.8% per year) are forecast to grow slower than the US market (15% per year).

High Growth Earnings: ABT's earnings are forecast to grow, but not significantly.

Revenue vs Market: ABT's revenue (6.5% per year) is forecast to grow slower than the US market (8.7% per year).

High Growth Revenue: ABT's revenue (6.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ABT's Return on Equity is forecast to be high in 3 years time (21.5%)

Abbott Laboratories Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Recent updates

A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Driving Value By Scaling Innovations

Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors

Second quarter 2024 earnings: EPS misses analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough

Upcoming dividend of US$0.55 per share

Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth-Defensive Index

These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Abbott Laboratories to Report Q2, 2024 Results on Jul 18, 2024

Purchasers of Certain PediaSure Products in California May Have Their Rights Affected by a Class Action Lawsuit

Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health

First quarter dividend of US$0.55 announced

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024

Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Why I Agree With Wall Street On This One

Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock

Executive Vice President of Finance notifies of intention to sell stock

New minor risk - Insider selling

Insider recently sold US$2.4m worth of stock

First quarter 2024 earnings: EPS exceeds analyst expectations

First quarter 2024 earnings: EPS exceeds analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Upcoming dividend of US$0.55 per share

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now

Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly

Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024

Fourth quarter dividend of US$0.55 announced

Now 20% overvalued after recent price rise

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

Insider exercised options and sold US$2.6m worth of stock

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

The King Is Back: Abbott Laboratories' Path To >11% Annual Returns

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Full year 2023 earnings: EPS exceeds analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Insider notifies of intention to sell stock

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio

Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?

Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market

Abbott Announces New Late-Breaking Data That Show Advanced Heart Failure Patients Living with its HeartMate 3 Heart Pump

Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes

Abbott Laboratories Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Independent Director recently sold US$4.7m worth of stock

Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?

Independent Director notifies of intention to sell stock

Abbott Announces Late-Breaking Data from the LIFE-BTK Clinical Trial Evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies